HEALTH● LOW2d ago · Aug 30, 2026, 7:01 PM
Tenax finds benefit in sicker patient subgroup after Phase 3 trial miss
Seeking Alpha Tech · global
Tenax has identified a benefit in a sicker patient subgroup, despite missing its primary endpoint in a Phase 3 trial. This finding could indicate specific efficacy for a targeted patient population.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH35m agoLiving and surviving the Black woman’s cursePremium TimesHEALTH1h agoGaps found in air pollution control measures at units in Edayar industrial areaThe HinduHEALTH2h agoNSIA saves Nigeria $200m in medical tourismVanguard NigeriaHEALTH2h agoINVESTIGATION: Despite billions of naira spent in the health sector, challenges remain in Osun’s rural PHCsPremium Times